<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604786</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00007520</org_study_id>
    <secondary_id>U19AI070345</secondary_id>
    <nct_id>NCT00604786</nct_id>
  </id_info>
  <brief_title>The Effect of Omalizumab on Responses to Cat Allergen Challenge</brief_title>
  <official_title>Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to study the effects of the drug omalizumab (Xolair) in people
      with cat allergies. The investigators will use omalizumab to study changes in the cells in
      the nose, skin and blood that cause allergies. The investigators predict that cells in the
      blood will be effected before cells in the nose or skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Omalizumab is a monoclonal antibody directed against Immunoglobulin E (IgE) and is
      FDA-approved for use in allergic asthma, though its clinical role is not precisely defined.
      It binds IgE on the same site of the Fc domain as the high affinity IgE receptor (FcεRI), and
      therefore, blocks the interaction between IgE and mast cells or basophils. It, therefore, may
      be used as a mechanistic tool in the study of IgE. As IgE levels are reduced with omalizumab,
      FcεRI expression on human basophils is reduced. This reduction of basophil receptors and
      allergen induced activation is pronounced within 7 days of the initial administration and is
      reversible once omalizumab administration is discontinued. The omalizumab-induced reductions
      in mast cell FcεRI expression and function is unchanged at day 7 and significantly reduced by
      day 70. These changes were based upon intravenously administered omalizumab at a dose of 0.03
      mg/kg/IU IgE/mL in a total of three subjects. We propose to exploit the kinetics of faster
      omalizumab effects on circulating basophils relative to tissue mast cells to elucidate the
      role of the basophil versus mast cell activation in nasal airway allergen challenge, which
      has not been studied to date.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Basophil Surface IgE</measure>
    <time_frame>Change from baseline to 3.5 months</time_frame>
    <description>Flow cytometry in mean fluorescence units.
100%*[(3.5 month value minus baseline value)/baseline value]</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Omalizumab subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omalizumab</intervention_name>
    <description>Dosing is based on IgE level and weight given every 2 or 4 weeks</description>
    <arm_group_label>Omalizumab subcutaneous</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Dosing is based on IgE level and weight given every 2 or 4 weeks</description>
    <arm_group_label>Placebo Subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and provide informed consent

          -  Male or Female (non-pregnant), age 18-50

          -  Females must be: Surgically sterile (hysterectomy, bilateral oophorectomy, bilateral
             tubal ligation), OR postmenopausal (at least 1 year since last menses), OR using a
             medically acceptable form of birth control throughout the duration of the study.

          -  Clinical history of seasonal or perennial allergic rhinitis for at least two years,
             with or without mild persistent asthma

          -  Positive puncture skin test greater than or equal to 5 mm diluent control

          -  Positive Immunocap to Fel d 1 &gt; 0.35 kallikrein unit/L

          -  Positive intranasal cat allergen challenge as defined by &gt; 5 sneezes or a tripling of
             measured nasal lavage mediators

          -  In vitro assay of basophil responsiveness to cat allergen with greater than 20%
             histamine release

          -  The use of antihistamines, cromolyn, leukotriene modifiers and other non-steroid
             (astelin and topical decongestants), nasal medications will be allowed, but they will
             be withheld for 5 days prior to each nasal allergen provocation session. Inhaled
             corticosteroids for mild asthma will be permissible.

          -  No known contraindications to therapy with omalizumab

        Exclusion Criteria:

          -  Asthma with forced expiratory volume at one second (FEV1) &lt; 80%, moderate to severe
             asthma classification per National Asthma Education and Prevention Program Expert
             Panel (NAEP) Standards (1997 National Asthma Education and Prevention Program Expert
             Panel Report II guidelines)

          -  Serum IgE levels less than 30 IU/mL or greater than 700 IU/mL at the time of
             enrollment will be excluded

          -  Unexplained elevation of erythrocyte sedimentation rate (ESR), hematocrit &lt; 32%, white
             blood cell (WBC) count 2400/microliter lower limit of normal, platelet &lt;
             75000/microliter, creatinine &gt; 141.4 micromolar/L, or aspartate aminotransferase (AST)
             &gt; 100 IU/L

          -  Body weight less than 30 kg or greater than 150 kg will be excluded.

          -  Plans to become pregnant or breastfeed will be excluded from the study

          -  A perforated nasal septum, structural nasal defect, large nasal polyps causing
             obstruction, evidence of acute or chronic sinusitis

          -  A life expectancy less than 6 months

          -  A terminal illness as determined by the investigator

          -  A history of malignancy, anaphylaxis or bleeding disorder are also exclusion
             illnesses.

          -  Mental illness or history of drug or alcohol abuse that, in the opinion of the
             investigator, would interfere with the participant's ability to comply with study
             requirements.

          -  Inability or unwillingness of a participant to give written informed consent or comply
             with study protocol

          -  Use of any investigational drugs within 8 weeks of participation

          -  Contraindications to omalizumab include patients with a previous hypersensitivity to
             omalizumab

          -  Recent recipient of any licensed or investigational live attenuated vaccine(s) within
             two months of study initiation such as flu mist.

          -  Prior use of omalizumab

          -  Frequent sinusitis (&gt;2/ documented episodes per year) or active sinusitis within 2
             weeks of enrollment

          -  Use of immunotherapy within the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarbjit S Saini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Asthma and Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/allergy/new/vs.html</url>
    <description>Study contact information</description>
  </link>
  <reference>
    <citation>Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006 Jun 22;354(25):2689-95. Review.</citation>
    <PMID>16790701</PMID>
  </reference>
  <reference>
    <citation>Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. Humanization of an antibody directed against IgE. J Immunol. 1993 Sep 1;151(5):2623-32.</citation>
    <PMID>8360482</PMID>
  </reference>
  <reference>
    <citation>Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 2):S6-11. Review.</citation>
    <PMID>11704611</PMID>
  </reference>
  <reference>
    <citation>MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997 Feb 1;158(3):1438-45.</citation>
    <PMID>9013989</PMID>
  </reference>
  <reference>
    <citation>Saini SS, MacGlashan DW Jr, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999 May 1;162(9):5624-30.</citation>
    <PMID>10228046</PMID>
  </reference>
  <reference>
    <citation>Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527-30.</citation>
    <PMID>15356552</PMID>
  </reference>
  <reference>
    <citation>Proud D, Bailey GS, Naclerio RM, Reynolds CJ, Cruz AA, Eggleston PA, Lichtenstein LM, Togias AG. Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. J Allergy Clin Immunol. 1992 Jun;89(6):1098-110.</citation>
    <PMID>1607547</PMID>
  </reference>
  <reference>
    <citation>Nathan RA, Eccles R, Howarth PH, Steinsvåg SK, Togias A. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol. 2005 Mar;115(3 Suppl 1):S442-59. Review.</citation>
    <PMID>15746882</PMID>
  </reference>
  <reference>
    <citation>Naclerio RM, Proud D, Togias AG, Adkinson NF Jr, Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985 Jul 11;313(2):65-70.</citation>
    <PMID>2582257</PMID>
  </reference>
  <reference>
    <citation>Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004 Feb;113(2):297-302.</citation>
    <PMID>14767445</PMID>
  </reference>
  <reference>
    <citation>Hanf G, Noga O, O'Connor A, Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J. 2004 Mar;23(3):414-8.</citation>
    <PMID>15065831</PMID>
  </reference>
  <reference>
    <citation>Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair D, Davancaze T, Adelman D. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol. 2004 Sep;93(3):243-8.</citation>
    <PMID>15478383</PMID>
  </reference>
  <reference>
    <citation>Pods R, Ross D, van Hülst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy. 2003 Nov;58(11):1165-70.</citation>
    <PMID>14616128</PMID>
  </reference>
  <reference>
    <citation>Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol. 2001 Jun;24(6):682-7.</citation>
    <PMID>11415932</PMID>
  </reference>
  <reference>
    <citation>Salib RJ, Lau LC, Howarth PH. Nasal lavage fluid concentrations of eotaxin-1 (CCL11) in naturally occurring allergic rhinitis: relationship to disease activity, nasal luminal eosinophil influx, and plasma protein exudation. Clin Exp Allergy. 2005 Aug;35(8):995-1002.</citation>
    <PMID>16120080</PMID>
  </reference>
  <reference>
    <citation>Terada N, Hamano N, Kim WJ, Hirai K, Nakajima T, Yamada H, Kawasaki H, Yamashita T, Kishi H, Nomura T, Numata T, Yoshie O, Konno A. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med. 2001 Aug 15;164(4):575-9.</citation>
    <PMID>11520718</PMID>
  </reference>
  <reference>
    <citation>Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, Kay AB. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol. 2005 Sep;116(3):558-64.</citation>
    <PMID>16159624</PMID>
  </reference>
  <reference>
    <citation>Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005 Mar;60(3):302-8.</citation>
    <PMID>15679714</PMID>
  </reference>
  <reference>
    <citation>Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005 Mar;60(3):309-16.</citation>
    <PMID>15679715</PMID>
  </reference>
  <reference>
    <citation>Casale TB. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 2):S18-21. Review.</citation>
    <PMID>11704613</PMID>
  </reference>
  <reference>
    <citation>Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandström T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000 Aug;106(2):253-9.</citation>
    <PMID>10932067</PMID>
  </reference>
  <reference>
    <citation>Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003 Aug;91(2):160-7.</citation>
    <PMID>12952110</PMID>
  </reference>
  <reference>
    <citation>Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002 Feb;109(2):274-80.</citation>
    <PMID>11842297</PMID>
  </reference>
  <reference>
    <citation>Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB Jr, Adelman DC. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997 Jul;100(1):110-21.</citation>
    <PMID>9257795</PMID>
  </reference>
  <reference>
    <citation>Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol. 2005 Aug;29(1):31-48. Review.</citation>
    <PMID>16222082</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>December 4, 2013</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Basophils</keyword>
  <keyword>Mast Cells</keyword>
  <keyword>IgE</keyword>
  <keyword>IgE receptors</keyword>
  <keyword>omalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab Subcutaneous</title>
          <description>This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and immunoglobulin E (IgE) based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Subcutaneous</title>
          <description>This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment</title>
          <description>This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
omalizumab: IgE 30-100 int. units/mL: 30-90 kg: 150 mg every 4 weeks &gt;90-150 kg: 300 mg every 4 weeks
IgE &gt;100-200 int. units/mL:
30-90 kg: 300 mg every 4 weeks &gt;90-150 kg: 225 mg every 2 weeks
IgE &gt;200-300 int. units/mL:
30-60 kg: 300 mg every 4 weeks &gt;60-90 kg: 225 mg every 2 weeks &gt;90-150 kg: 300 mg every 2 weeks
IgE &gt;300-400 int. units/mL:
30-70 kg: 225 mg every 2 weeks &gt;70-90 kg: 300 mg every 2 weeks &gt;90 kg: Do not administer dose
IgE &gt;400-500 int. units/mL:
30-70 kg: 300 mg every 2 weeks &gt;70-90 kg: 375 mg every 2 weeks &gt;90 kg: Do not administer dose
IgE &gt;500-600 int. units/mL:
30-60 kg: 300 mg every 2 weeks &gt;60-70 kg: 375 mg every 2 weeks &gt;70 kg: Do not administer dose
IgE &gt;600-700 int. units/mL:
30-60 kg: 375 mg every 2 weeks &gt;60 kg: Do not administer dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: IgE 30-100 int. units/mL: 30-90 kg: placebo every 4 weeks &gt;90-150 kg: placebo every 4 weeks
IgE &gt;100-200 int. units/mL:
30-90 kg: placebo every 4 weeks &gt;90-150 kg: placebo every 2 weeks
IgE &gt;200-300 int. units/mL:
30-60 kg: placebo every 4 weeks &gt;60-90 kg: placebo every 2 weeks &gt;90-150 kg: placebo every 2 weeks
IgE &gt;300-400 int. units/mL:
30-70 kg: placebo every 2 weeks &gt;70-90 kg: placebo every 2 weeks &gt;90 kg: Do not administer dose
IgE &gt;400-500 int. units/mL:
30-70 kg: placebo every 2 weeks &gt;70-90 kg: placebo every 2 weeks &gt;90 kg: Do not administer dose
IgE &gt;500-600 int. units/mL:
30-60 kg: placebo every 2 weeks &gt;60-70 kg: placebo every 2 weeks &gt;70 kg: Do not administer dose
IgE &gt;600-700 int. units/mL:
30-60 kg: placebo every 2 weeks &gt;60 kg: Do not administer dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" lower_limit="24" upper_limit="47"/>
                    <measurement group_id="B2" value="32.3" lower_limit="25" upper_limit="49"/>
                    <measurement group_id="B3" value="31" lower_limit="24" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Basophil Surface IgE</title>
        <description>Flow cytometry in mean fluorescence units.
100%*[(3.5 month value minus baseline value)/baseline value]</description>
        <time_frame>Change from baseline to 3.5 months</time_frame>
        <population>2 participants on the Omalizumab subcutaneous group moved and were therefore lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab Subcutaneous</title>
            <description>This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Subcutaneous</title>
            <description>This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basophil Surface IgE</title>
          <description>Flow cytometry in mean fluorescence units.
100%*[(3.5 month value minus baseline value)/baseline value]</description>
          <population>2 participants on the Omalizumab subcutaneous group moved and were therefore lost to follow-up.</population>
          <units>percentage of basophil surface IgE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95" spread="3"/>
                    <measurement group_id="O2" value="-10" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3.5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab Subcutaneous</title>
          <description>This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Subcutaneous</title>
          <description>This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>2 subject in active group did not finish the study, small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarbjit S. Saini</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-550-2129</phone>
      <email>ssaini@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

